In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until condition progression or even the individuals are not able to tolerate the study drugs. For all move cytometry experiments, ten,000 cells for every replicate have been https://abbv-744-and-other-brd4-i80246.blog-mall.com/32518814/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients